Abstract The purpose of this study is to evaluate the effectiveness and safety of mycophenolate mofetil (MMF) for inducing and/or maintaining remission of lupus nephritis (LN). This is a retrospective study of 25 LN patients consecutively treated with MMF. The primary outcome was complete renal remission (CR) defined by urine protein/ creatinine ratio ≤0.5 g/g and inactive urine sediment and serum creatinine within <15% above baseline. For induction, 21 episodes of active, moderate to severe LN were treated with MMF. Twelve cases (57%) achieved CR over a median of 8.5 months. Of 13 patients who had LN for <12 months and took ≥2 g/day of MMF, 11 achieved CR, compared to one out of the eight patients who did not meet both criteria (p=0.0022). For maintenance therapy, 15 patients received MMF for a median of 20 months (range 5-55 months). Two patients (13%) experienced renal flares while taking MMF. Most adverse events were transient and did not require change in therapy. This study suggests that MMF is an effective treatment for both induction and maintenance of remission of moderate to severe LN with a relatively favorable safety profile. Early treatment and a dose ≥2 g/day are essential for optimal outcome. CR may take >6 months.
Introduction
Lupus nephritis (LN) is a common and potentially devastating manifestation of systemic lupus erythematosus (SLE) that can lead to kidney failure and premature death. Intravenous cyclophosphamide (IV CYC) has been regarded as the standard of care for induction therapy for severe LN [1] . However, CYC treatment does not always result in remission and is potentially associated with serious adverse effects that can include severe infections, bone marrow suppression, premature gonadal failure, hemorrhagic cystitis, and malignancy. Mycophenolate mofetil (MMF) has emerged as another option for induction of remission of moderate to severe LN with recent data suggesting better renal and overall outcomes compared to CYC [2] . Moreover, MMF has recently been shown to be more effective than quarterly IV CYC for maintenance of remission with fewer adverse events [3] . A major concern remains that these studies are of relatively short duration, while longer-term data are available for CYC.
The objective of this study was to evaluate the effectiveness, tolerability, and safety of MMF, in combination with corticosteroids, in inducing and/or maintaining remission of LN in a noncontrolled setting.
Materials and methods
We conducted a retrospective observational study of 25 LN patients seen at MetroHealth Medical Center (MHMC) in a dedicated urban lupus clinic who were consecutively treated with MMF for induction and/or maintenance of remission between December 2000 and October 2006. This study was approved by the MHMC Institutional Review Board.
Inclusion criteria
We included all patients who received MMF at the MHMC lupus clinic during the study period, met the American College of Rheumatology 1997 revised classification criteria for SLE [4] , and had active LN as defined by the presence of persistent proteinuria of >0.5 g/g creatinine in a random urine sample or >500 mg in a 24-h urine collection, in addition to at least one of the following: active urine sediment, positive anti-dsDNA antibody, and/or hypocomplementemia [5] . All patients who received MMF for induction of remission, except two, were consecutive LN patients who were cared for by a single rheumatologist and were given MMF as the initial agent. Of the two other patients, one had failed initial CYC therapy. The selection of MMF for maintenance was mainly determined by the response to it as an initial induction therapy.
Exclusion criteria None.
MMF was administered at a starting dose of 0.5 g bid and titrated up to a total daily dose of 3 g over a few weeks. All patients received concomitant corticosteroid. The initial dose was determined by the treating physician based on acuity and severity of renal involvement and extrarenal symptoms but occasionally influenced by some patients declining higher doses of steroids. The median initial prednisone dose was 30 mg/day (range 10-60 mg/day) with only one patient receiving pulse methylprednisolone 1 g/day for 3 days. Prednisone dose tapering was based on clinical improvement
The primary outcome measure was complete renal remission (CR) as defined by urine protein/creatinine ratio of ≤0.5 g/g, urine analysis with no cellular casts and ≤5 red blood cells, and stable serum creatinine within <15% above baseline. Baseline creatinine was defined as the value of serum creatinine immediately prior to initiation of MMF. Secondary outcome measures were: (1) partial renal remission (PR) as defined by: ≥50% improvement in proteinuria and/or serum creatinine without worsening (within <15%) of either measurement; (2) renal flare defined as increase of >50% of baseline urine protein/creatinine ratio and/or increase in serum creatinine of >20% of baseline; and (3) adverse events. Other secondary outcome measures were corticosteroid dose and final values of urine protein/ creatinine ratio, serum creatinine, serum albumin, anti-DNA antibody titers, and complement components C3 and C4. We also determined time to normalization of serum creatinine (to ≤1 mg/dL) and to initial improvement in proteinuria defined by 30% reduction in urine protein/creatinine ratio.
Relevant baseline variables included: demographics (race, gender, and age at diagnosis); relevant comorbid disorders (uncontrolled hypertension, determined by blood pressure higher than 140/90 more than three times in the year prior to initiating MMF; history of diabetes, determined by fasting blood glucose ≥126 mg/dL more than once before initiation of treatment); duration of SLE, determined from the first time the ACR criteria were met; and duration of LN, determined from the first time a proteinuria of >0.5 g/g creatinine in a random urine sample or >0.5 g in 24-h urine was documented. Use of prednisone was meticulously recorded by reviewing all notes in electronic medical records.
Electronic medical records were reviewed to identify all patients who received MMF at the MHMC lupus clinic for induction and/or maintenance of remission of LN between December 2000 and October 2006. Baseline characteristics and initial laboratory values were determined at the time of MMF initiation. The entire electronic medical record was thoroughly reviewed from the time of drug start until May 2007 and included all clinic and emergency room visits, hospitalization records, telephone encounters, laboratory tests, and radiographic reports. Data were entered into a chart extraction form. Patients were deidentified using a key that only the primary investigators have access to. The key is kept in a locked file separately from patients' data.
The one-sample proportions test was used to calculate proportions and 95% confidence intervals. The paired samples Wilcoxon test was used to compare values before and after treatment with MMF for various laboratory data. Differences in the characteristics of responders versus nonresponders were analyzed using Wilcoxon signed rank test for continuous variables and Fisher's exact test for categorical variables. Continuous variables categorization was attempted at different values to investigate the possibility of association with the outcome and significant cutoffs are reported. However, adjusting for covariates using methods such as multivariate logistic regression was not possible because of the small sample size and the small number of patients with the outcome. A two-sided p value was used in all statistical analyses and a p<0.05 was considered the cutoff for statistical significance. We used the statistical software R 2.5.1 and SAS 9.1 to conduct our analysis.
Results
Most patients were female (18 patients, 86%). AfricanAmerican patients constituted the largest proportion of our cohort (11 patients, 52%). The majority of patients received concurrent treatment with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (19 patients, 90%) and hydroxychloroquine (19 patients, 90%). All patients received corticosteroids. Fourteen patients (67%) underwent a kidney biopsy; of these, seven (50%) had WHO class IV membranoproliferative glomerulonephritis. The values for urine, protein/creatinine ratio, and serum creatinine at the time of MMF initiation were missing in two patients; however, the presence of active LN was confirmed with laboratory values before and after the initiation of therapy.
Sixteen of 19 patients (84%) had evidence of severe LN with elevated serum creatinine (>1.0 mg/dL) and/or nephrotic range proteinuria (>3 g/g creatinine). The other three patients were considered to have moderately severe LN with proteinuria >2 g/g creatinine but with a normal serum creatinine (≤1.0 mg/dL). One of the patients had failed to show any evidence of response to IV CYC for 3 months prior to the initiation of MMF. Most of our patients were young with a median age of 26 years. The duration of LN was 12 months or more in six patients (29%). All patients had hypoalbuminemia (<3.4 g/dL) at the start. Median initial prednisone dose was 30 mg daily with only one patient receiving 1 g pulse methylprednisolone daily for 3 days. Initial prednisone dose was ≤20 mg/day in seven patients (Tables 1 and 2 ).
Primary outcome
For remission induction, 21 episodes (in 19 patients) of active, moderate to severe LN were treated with MMF. Twelve cases (57%) achieved CR (95%CI=34-77%). Median time to CR was 8.5 months (range 2-21 months).
Secondary outcome measures
Fifteen patients (71%) achieved at least PR (95%CI=48-88%) over a median time period of 4 months (range 1-16 months). Three patients who did not achieve partial remission with MMF were switched to monthly IV CYC after 3, 4, and 7 months, respectively. None of these achieved at least PR with CYC either.
There was statistically significant improvement in the levels of urine protein, serum albumin, complement components C3 and C4, and anti-DNA antibody level at 3 months. The improvement continued progressively through the sixth month and was sustained through the end of MMF therapy and at last follow-up (last evaluation during the study period after discontinuing MMF).
The median time to normalization of serum creatinine was 1 month (range 0-2 months) in those whose creatinine was abnormal at baseline and improved with treatment (N=9). The median time to 30% reduction in proteinuria was 2 months (range 1-6 months; N=16). The median time for either normalization of serum creatinine or 30% reduction in proteinuria was 1 month (range 1-6 months; N=16).
During treatment with MMF, there was marked reduction in corticosteroid dose from a median dose of 30 mg daily at the start to 15 mg daily at 3 months (p=0.001) and to 5 mg per day at 6 months (p=0.0007) (Fig. 1) . Tables 3 and 4 show the association of several variables with complete remission and at least partial remission using univariate analyses, respectively. An average MMF dose of ≥2 g/day over the first 3 months was the only variable with statistically significant association with both complete remission and at least partial remission (p=0.02 and p= 0.0025, respectively). Of 17 patients who took ≥2 g of 
Maintenance therapy
Eleven patients out of the 12 reported above were maintained on MMF. An additional four patients were started on MMF after achieving complete remission with other regimens (one with CYC, one with azathioprine, one with methotrexate, and one with high-dose corticosteroids alone). These 15 patients received MMF for a median of 20 months (range 5-55 months). Median follow-up was 26 months (range 10-68 months). Median average prednisone dose while taking MMF was minimal at 3 mg/day (25th and 75th percentile=0 and 7.75 mg/day). Two patients (13%, 95%CI=2-42%) experienced renal flares while taking MMF, at months 17 and 22 of MMF therapy; one of them had reduced the MMF dose to 1 g/day. A third patient experienced a flare 17 months after discontinuing MMF. Of the total three patients who experienced renal flares, only one was taking hydroxychloroquine, compared to 11 patients taking hydroxychloroquine out of 12 patients without flares (p=0.08).
Adverse events
Overall, 27 courses of MMF were received by 25 patients for remission induction and/or maintenance. The median duration of treatment was 19 months (range 0.2-55 months). The median follow-up time was 26 months (range 10-76 months). The most common adverse events, viral upper respiratory tract infections, upper gastrointestinal symptoms, and diarrhea, were mild and transient and did not require change in therapy except in one patient who did not tolerate dose escalation beyond 1 g/day due to persistent diarrhea, nausea, and vomiting. Two more patients discontinued MMF after 1 week and 1 month because of severe nausea and hives, respectively. There were no serious pyogenic infections or amenorrhea among premenopausal females. One patient, who was nonadherent to medical treatment, died suddenly 3 months after discontinuing MMF with severe nephrotic syndrome and normal serum creatinine.
Discussion
Our study reports the cumulative experience with the use of MMF for induction and/or maintenance of remission of LN from a single lupus clinic serving an urban population. African-American and Hispanic patients, groups shown to have worse prognosis [6] , constituted the largest proportion of our cohort; the majority of them had evidence of severe LN. Most patients achieved at least partial remission when MMF was used initially for induction. The effectiveness of MMF was most noticeable when treatment was initiated at an early stage and patients received a dose of at least 2 g/day.
The median time to complete remission was 8.5 months, which may be somewhat more delayed than many clinicians have appreciated. Resolution of proteinuria usually takes much longer than normalization of other markers [3, 7] , and some degree of proteinuria and hematuria may persist despite remission. We noted, however, that clear initial improvement in proteinuria is seen within a shorter period of time (median 2 months). More importantly, the median time to normalization of serum creatinine was 1 month (range 0-2 months) in responders. Undoubtedly, the initial use of corticosteroid therapy contributes to the early response. Nevertheless, these observations may be helpful in setting expectations during treatment. The initial corticosteroid dose in our study patients was generally lower than is usually used in randomized clinical trials (median 30 mg/day) and the dose at 6 months was fairly low. Given the serious side effects of high doses of corticosteroids, this is of great interest to rheumatologists or nephrologists treating LN.
During maintenance therapy, only two patients experienced renal flares over a median follow-up of 26 months (range 10-68 months) while taking MMF and a minimal prednisone dose. MMF was relatively safe and welltolerated, without occurrence of serious infections or death attributable to the drug.
Some of the limitations of our study include its retrospective design and small sample size. The small number of patients with the outcome precluded risk adjustment with methods such as multivariate logistic regression. Assignment of MMF for the maintenance therapy was not random, which implies potential selection bias; however, there was virtually no selection issues during the induction phase, as the vast majority of patients were consecutive LN patients seen by a single rheumatologist. Second, our outcomes were defined based on laboratory, not pathological, findings. Complete resolution of proteinuria often lags behind improvement of other measures of LN remission. Hematuria may not necessarily reflect active disease as it could be the result of other causes such as structural damage, renal cysts, or infection. Moreover, persistent elevation of serum creatinine may sometimes reflect structural damage from scarring or vascular disease rather than active LN. The fact that this was a retrospective study explains why a kidney biopsy was not obligatory before initiating treatment or for evaluating response, which could have added important information. Lastly, with the retrospective nature of the study, minor adverse events might have been underestimated, but this is less likely with serious events.
Nonetheless, a main strength of our study is that it presents data of longer duration than is available from previously published reports on MMF for induction of remission of LN in the United States. The only data of longer duration came from Hong Kong [8] with a population that is racially different from our population. It provides data on the timing and long-term rate of remission as well as predictors of remission and relapse with MMF use. It indicates that a later time point than what has been usually used in recent clinical trials, i.e., 6 months, should be used to evaluate the effectiveness of an induction regimen for LN. It also confirms the relative long-term safety of this drug. This study reports recent data from reallife experience from patients with severe disease. Our data support the rationale for a controlled study to compare MMF and CYC long-term outcomes. Having multiple options to present to patients is always desirable. Whether MMF or another agent is chosen as the initial treatment, it is prudent that treatment is initiated as early as possible, adequate dose is used, signs of initial response be assessed early, and a change in strategy is promptly applied when patients fail to show expected improvement.
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